CONFIDENTIAL
04 · 2026
Lipedema action plan
A personalized synthesis for a premenopausal Stage II Type III lipedema case (hip-thigh-calf distribution, feet spared), with 22 years of unrecognized progression and an unusually favorable intervention window.
- Prepared for
- Sample · M.H., 41
- Condition
- Lipedema Stage II, Type III
- Pages
- 38
- Lead reviewers
- Giannini · Paramonov
- 01Executive summary
- 02Case synthesis
- 03Disease model — your version
- 04Specialist pathway
- 05Clinical workup and imaging
- 06Signal analysis — your activation map
- 07Genetic findings — variant-level review
- 08DEXA body composition
- 09Intervention prioritization — Ternary Method applied
- 10Medical therapy — discussion points
- 11Supplement framework
- 12Compression, MLD, and movement
- 13Diet, sleep, and recovery
- 14Monitoring plan
- 1590-day execution blueprint
- 16Questions for your physicians
- 17Resources and communities
Executive summary
What this plan says and the three moves that matter most in the next 30 days.
A 41-year-old premenopausal woman with a 22-year history of progressively disproportionate lower-body adipose tissue — diagnosed with Stage II Type III Lipedemain November 2025 after 14 years of being told she was “just overweight.” Premenopausal, still functional, organ function preserved, no first-line lipedema intervention ever offered. Unusually favorable window.
- 01
- Certified lymphedema therapist evaluation + complete decongestive therapy within 14 days. Complete decongestive therapy (MLD + flat-knit compression + multilayer bandaging during decongestion) is the single highest-yield, lowest-risk, best-evidenced intervention for lipedema at any stage. Never had it. Phase 1: 2–4 weeks of daily treatment. Phase 2: self-management with custom flat-knit garments indefinitely. Request CLT-LANA credential specifically.
- 02
- Hormonal review of drospirenone OC + estrogen-dominance workup. Lipedema flares are classically estrogen-driven. Day-21 panel shows estradiol 218 with progesterone 4.2 — an estrogen-dominance pattern. 11-year drospirenone history spans the Stage I → Stage II progression. A structured conversation with a lipedema-informed gynecologist or reproductive endocrinologist about a 6-month trial of non-hormonal or progestin-only contraceptive is high-leverage.
- 03
- Lipedema-specialist surgical consult — not for surgery yet, but to stage the decision. Lymph-sparing liposuction (water-assisted or tumescent with manual extraction) is the only intervention shown to durably reduce lipedema tissue. You are an unusually favorable candidate. Begin consultation now so that at month 9–12 the decision is made with a surgeon who has performed 500+ lipedema-specific procedures, not a general plastic surgeon.
- 04
- Endocrinology referral for Hashimoto’s + levothyroxine discussion. TPO 142, TSH 4.2, fT4 low-normal — never identified before. Almost certainly contributing to fatigue, cognitive fog, and suppressed thyroid hormone conversion. Endocrinology referral indicated; selenium supplementation in parallel.
Case synthesis
Timeline, clinical picture, and stated goals reconstructed into one coherent narrative.
Clinical timeline
| Year | Event |
|---|---|
| ~2004 | Puberty onset at age 13; disproportionate lower-body adipose appearance begins. Attributed to family body type. |
| 2011 | First pregnancy; lipedema accelerates postpartum. PCP attributes to 'baby weight.' |
| 2013 | Second pregnancy; further acceleration. Combined OC (drospirenone/ethinyl estradiol) started postpartum. |
| 2014 – 2021 | Multiple weight-loss programs (Weight Watchers × 2). Weight loss proportional on arms, face, trunk — but NOT hips/thighs. Classic lipedema pattern not recognized. |
| 2020 | Tissue becomes painful to palpation. Bruising frequency increases. |
| Nov 2025 | Vascular medicine physician at Mass General confirms Stage II Type III Lipedema diagnosis. 14-year diagnostic delay. |
| 2026 – present | Still fully functional. Swims 2–3× weekly. Stopped running age 32 due to thigh tissue. Daughters showing early pubertal adipose asymmetry. |
Stated goals (kickoff call, Feb 20, 2026)
- “I want to stop the progression. I do not need my legs to shrink — I need them to stay how they are.”
- “I want to know whether to have surgery, and if so, when, and with whom.”
- “I want pain that does not require planning my life around what chair I have to sit on.”
- “I want a framework for my daughters that does not rely on the medical system recognizing this in time.”
- “I want to be taken seriously by people who treat this as a real disease.”
Current medications & prior therapy trials
Drospirenone / ethinyl estradiol OC (11 years continuous). Vitamin D3 1,000 IU daily (inadequate dose). No pain medications. Prior trials: Weight Watchers × 2 (with classic lipedema-preserved-disproportion pattern), yoga and pilates (subjective mobility benefit, none on tissue volume), OTC 15–20 mmHg compression purchased six months ago and abandoned after one week (wrong compression class, wrong fit).
Disease model — your version
Four upstream drivers feed the downstream lipedema phenotype. Three of four are modifiable.
The current consensus model (Herbst 2021 Standard of Care; Allen-Rowlands 2023 review) identifies four contributors acting in combination: estrogen signaling in subcutaneous adipocytes, lymphatic microangiopathy, low-grade adipose inflammation with capillary fragility, and hereditary predisposition with variable expressivity. Unlike Dercum’s Disease, lipedema is not a neuropathic pain disorder primarily — pain is secondary to tissue inflammation, lymphatic load, and mechanical compression.
What that means practically
- Lymphatic load is the single most modifiable driver. CDT addresses tissue load, inflammation, and pain in one intervention.
- The hormonal lever is parallel, not sequential. Drospirenone discontinuation trial is a Week 2–3 priority, not a Month 3 afterthought.
- Genetic signal drives two conversations: surgical timing for you, and early surveillance for your daughters.
- Metabolic work compounds the others but is not gating. Mediterranean pattern + graded movement over 90 days.
See this depth applied to your condition.
This is a sample built on a composite case — we don’t publish the full sample. A Ternary Brief on your own situation is free and takes about three minutes.
You’re reading 3 of 17 sections. The full Precision Deep Dive continues with specialist pathway, clinical workup and imaging, signal analysis, genetic findings, and more.
Educational sample on a composite case. Your brief and any report are built from your own situation and are never shared.